Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

References

• TreuerTLiuCYSalazarGUse of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisitedAsia Pac Psychiatry20135421923023857712
   PubMed Web of Science ®Google Scholar
• Japanese Society of Mood DisordersTreatment Guideline II: Major Depressive Disorder, 2012 Ver. 1Japanese Society of Mood Disorders7262012 Japanese
   Google Scholar
• PapakostasGIThaseMEFavaMNelsonJCSheltonRCAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsBiol Psychiatry200762111217122717588546
   PubMed Web of Science ®Google Scholar
• ThaseMEPritchettYLOssannaMJSwindleRWXuJDetkeMJEfficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderJ Clin Psychopharmacol200727667267618004135
   PubMed Web of Science ®Google Scholar
• ThaseMEOverview of antidepressant therapyManag Care2001108 Suppl6911729437
   PubMedGoogle Scholar
• HansenRAGartlehnerGLohrKNGaynesBNCareyTSEfficacy and safety of second-generation antidepressants in the treatment of major depressive disorderAnn Intern Med2005143641542616172440
   PubMed Web of Science ®Google Scholar
• GartlehnerGGaynesBNHansenRAComparative benefits and harms of second-generation antidepressants: background paper for the American College of PhysiciansAnn Intern Med20081491073475019017592
   PubMed Web of Science ®Google Scholar
• GartlehnerGThalerKHansenRAGaynesBNThe general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysisDrug Saf200932121159117319916583
   PubMed Web of Science ®Google Scholar
• SmithDDempsterCGlanvilleJFreemantleNAndersonIEfficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysisBr J Psychiatry200218039640411983635
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceClinical practice guideline No 23. Depression: management of depression in primary and secondary careLondon, UKNational Institute for Clinical Excellence2004 Available from: http://www.nice.org.uk/guidance/cg23Accessed November 19, 2014
   Google Scholar
• GartlehnerGHansenRAMorganLCComparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysisAnn Intern Med20111551177278522147715
   PubMed Web of Science ®Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• LeePShuLXuXOnce-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and BrazilPsychiatry Clin Neurosci200761329530717472599
   PubMed Web of Science ®Google Scholar
• PigottTAPrakashAArnoldLMAaronsonSTMallinckrodtCHWohlreichMMDuloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorderCurr Med Res Opin20072361303131817559729
   PubMed Web of Science ®Google Scholar
• NierenbergAAGreistJHMallinckrodtCHDuloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority studyCurr Med Res Opin200723340141617288694
   PubMed Web of Science ®Google Scholar
• MallinckrodtCHPrakashAHoustonJPSwindleRDetkeMJFavaMDifferential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)Neuropsychobiology2007562–3738518037817
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders Text Revision (DSM-IV-TR)4th edWashington, DC, USAAmerican Psychiatric Association2000
   Google Scholar
• ThaseMESimonsADCahalaneJMcGearyJHardenTSeverity of depression and response to cognitive behavior therapyAm J Psychiatry199114867847892035722
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry1960231566214399272
   PubMed Web of Science ®Google Scholar
• HamiltonMThe assessment of anxiety states by ratingBr J Med Psychol1959321505513638508
   PubMed Web of Science ®Google Scholar
• MaierWPhilippMImproving the assessment of severity of depressive states: a reduction of the Hamilton Depression ScalePharmacopsychiatry1985181114115
   Web of Science ®Google Scholar
• ClearyPGuyWFactor analysis of the Hamilton Depression ScaleDrugs Exp Clin Res197711–2115120
   Google Scholar
• BechPGramLFDeinEJacobsenOVitgerJBolwigTGQuantitative rating of depressive statesActa Psychiatr Scand19755131611701136841
   PubMed Web of Science ®Google Scholar
• MartinezJMKatonWGreistJHA pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episodeInt Clin Psychopharmacol2012271172622027844
   PubMed Web of Science ®Google Scholar
• KatzMMTekellJLBowdenCLOnset and early behavioral effects of pharmacologically different antidepressants and placebo in depressionNeuropsychopharmacology200429356657914627997
   PubMed Web of Science ®Google Scholar
• MorilakDAFrazerAAntidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioral effects in depression and anxiety disordersInt J Neuropsychopharmacol20047219321815003145
   PubMed Web of Science ®Google Scholar